Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $106.00.

Several research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Wedbush reiterated an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. HC Wainwright lifted their price target on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday. Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Morgan Stanley upped their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, June 15th.

Disc Medicine Price Performance

NASDAQ:IRON opened at $77.44 on Friday. The stock has a market capitalization of $2.96 billion, a PE ratio of -11.77 and a beta of 1.00. Disc Medicine has a 1-year low of $40.00 and a 1-year high of $99.50. The firm has a fifty day simple moving average of $73.44 and a 200 day simple moving average of $69.73. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.17. On average, research analysts expect that Disc Medicine will post -6.62 EPS for the current fiscal year.

Insider Activity at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 33,000 shares of the firm’s stock in a transaction on Monday, July 13th. The stock was sold at an average price of $74.96, for a total transaction of $2,473,680.00. Following the completion of the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at $16,945,757.44. This trade represents a 12.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $72.66, for a total transaction of $704,802.00. Following the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $3,947,181.84. This trade represents a 15.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 105,712 shares of company stock worth $7,597,536. Company insiders own 3.76% of the company’s stock.

Institutional Trading of Disc Medicine

Several hedge funds and other institutional investors have recently modified their holdings of IRON. State of Wyoming acquired a new position in Disc Medicine in the 2nd quarter valued at about $25,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Disc Medicine during the fourth quarter worth approximately $33,000. KBC Group NV bought a new stake in shares of Disc Medicine during the fourth quarter worth approximately $80,000. Persistent Asset Partners Ltd acquired a new position in shares of Disc Medicine in the fourth quarter valued at approximately $141,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Disc Medicine by 36.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after purchasing an additional 490 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.